Since the 90's, the global burden of tuberculosis (TB) has been markedly influenced by the acquired immunodeficiency syndrome (AIDS) epidemic. HIV infection has been claimed as one of leading causes of the recrudescence of tuberculosis in developed countries. Likewise, an increasing proportion of tuberculosis is occurring in HIV-infected patients worldwide [1] .
Co-infection with Mycobacterium tuberculosis and HIV leads to alteration in the clinical course of both diseases [2, 3] . It has been demonstrated that HIVinfected persons have a much higher susceptibility to M. tuberculosis disease. Clinical manifestations of tuberculosis in HIV-patients are usually more severe, with diffuse pulmonary involvement, and frequent extrapulmonary dissemination [4] . In addition, M. tuberculosis has been shown to increase HIV-1 replication [5, 6] , and possibly progression to AIDS [7, 8] .
Thus, it is conceivable that the immune derangement found in co-infected patients differs from that of patients infected with either of these pathogens alone. It has been shown that co-infected patients have decreased proliferative response to M. tuberculosis antigens, and reduced production of IL-2 and IFNγ, compared to patients with tuberculosis and no HIV [8] .
T lymphocytes play a pivotal role in host responses to M. tuberculosis and HIV-1 infections. Immunophenotyping of peripheral T lymphocytes and expression of surface activation markers in HIVinfected patients has demonstrated an imbalance of naive and memory/effector cells on CD 4 + cells [9] and enhanced expression of activation surface markers, such as CD 38 , on the CD 8 + cells [10] . We have recently shown how M. tuberculosis infection and disease affect these parameters [11] . However, there is little information on these parameters in patients co-infected with M. tuberculosis and HIV-1. Most investigations conducted on patients with both M. tuberculosis and HIV-1 fail to estimate the contribution of each infection per se in the immune derangement seen in co-infected patients. We evaluated CD 4 + and CD 8 + T cell counts, the CD 4 + T lymphocytes subpopulations of naive and memory/effector cells, and the expression of CD 38 , a surface activation marker, on CD 8 + T lymphocytes in patients co-infected with both M. tuberculosis and HIV and in patients infected either with M. tuberculosis or HIV.
Materials and Methods
Patients and Healthy Volunteers. Institutional Review Board approved written informed consent was obtained from all participants, according to the Brazilian Ministry of Health Guidelines. Four groups of volunteers were enrolled: (1) the active TB group consisted of HIV-1 negative patients with recently diagnosed active pulmonary tuberculosis, defined by a medical history and clinical findings compatible with pulmonary tuberculosis, a thoracic roentgenogram showing lung involvement suggestive of tuberculosis, and isolation of M. tuberculosis from a respiratory tract specimen; (2) the asymptomatic HIV group consisted of HIV-1-infected individuals, as determined by an enzyme-linked immunosorbent assay (ELISA) and a confirmatory Western Blot or Indirect Immunofluorescence assay. All patients had CD 4 T lymphocyte counts of less than 350 cells/µL) and had no evidence of active opportunist disease; (3) the co-infected group consisted of HIV-1-infected patients who presented with tuberculosis, based on clinical and laboratory findings, as defined above, enrolled prior to tuberculosis treatment; (4) the control group consisted of healthy volunteers, who had two consecutive non-detectable delayed-type hypersensitivity intradermal reactions to a purified protein derivative, and had no evidence of active respiratory disease.
Monoclonal Antibodies and Sample Preparation. CD 27 phycoerythrin (PE, clone L128), CD 45 
Results
From August, 1999, to July, 2000, 61 subjects were enrolled in the four defined groups: active TB (n=20), asymptomatic HIV+ group (n=10), co-infected group (n=14), and healthy volunteers group (n=17). Age in years (mean± standard deviation) was nearly the same in the four groups (33±11, 30±6, 29±6 and 32±13, respectively). Figure 1A represents the absolute peripheral blood numbers of CD 4 + T lymphocytes and Figure 1B shows the percentage participation of the naive subpopulation (CD 45 RA + /CD 27 + ) among T CD 4 + cells. Significant differences between groups was observed in CD 4 + T counts in all pairwise comparisons, except between coinfected and the HIV+ asymptomatic group. *p<0.05 compared to TB and healthy volunteers. (Figure 2A ).
Immunophenotyping of T Cells in HIV/TB
The percentage of T CD 8 expressing CD 38 was different among the four groups (p=<0.001), with the lowest values presented by the healthy volunteers ( Figure 2B ). Asymptomatic HIV-1 patients had higher expression than tuberculosis patients, and HIV/TB patients were similar to asymptomatic HIV-1 patients, but had a higher expression than TB-patients (p<0.05).
Discussion
HIV-infected patients with tuberculosis had lower CD 4 + and CD 8 + T lymphocytes counts than patients with single TB or HIV infections, respectively. Both HIV-infected and TB patients presented lower CD 4 + T lymphocyte counts than healthy controls. Low CD 4 + T cell counts was an inclusion criterion for HIV patients (less than 350 cells/µL). This criterion, along with a lack of an ongoing opportunistic infection and antiretroviral therapy, was designed to enroll asymptomatic HIVpatients with established HIV-induced immune alterations. It is not unexpected that HIV-patients with opportunistic infections have lower CD 4 + T cell counts than asymptomatic patients. Thus, the tendency towards lower cell numbers seen in co-infected patients may reflect more advanced HIV disease in such individuals. However, one may consider a role for TB as a further factor for the decrease of T CD 4 + lymphocytes in such susceptible patients. This makes sense when we examine the depression of CD 4 + T lymphocyte counts found in the group of patients with tuberculosis and not infected by HIV [11] .
The decrease of CD 4 + T lymphocytes was found to be differentially distributed in naive, memory and effector subpopulations, with the differences in absolute cell numbers in each subpopulation reflecting what was observed in total T CD 4 + cells (data not shown). Although one may expect a change in the distribution of these subpopulations in the HIV/TB setting, as well as in each disease independently, we did not find differences in this study, which may be due to the small numbers of subjects in each group. A decrease in naive CD 4 + cells has been described in HIV-infected patients with advanced disease [9] . We recently evaluated CD 4 + T cell subpopulations in persons with TB infection (PPD positive skin test) and patients with disease, before and after treatment, and found a major impact on T CD 4 + cells, but again changes in the percentages of naive and memory/effector cells were not significantly different [11] .
We found that TB and HIV infection have different effects on CD 8 + T cell counts. In TB patients there was a decreased number of CD 8 + T lymphocytes, while the cell numbers were not altered in HIV-infected patients. In general these cells are found in enhanced numbers in HIV-infected patients during long periods of the natural progression of HIV infection [12] . The occurrence of TB in AIDS patients results in a strong reduction of CD 8 + T lymphocytes, compared to HIVinfection alone, with a trend towards absolute counts even lower than in patients with tuberculosis. This finding, coupled with the extremely low CD 4 + T cell counts, may contribute to the impaired cellular immunity seen in co-infected patients.
Expression of CD 38 on CD 8 + T lymphocytes is a useful tool to evaluate the state of cellular activation, which is higher in HIV-infected patients than in negative controls, increases as the disease advances, and has been shown to be a predictor of progression of this disease [13] . We have previously reported enhanced expression of CD 38 in patients with TB, compared to treated patients [11] . Our results support the hypothesis of augmented expression of CD 38 secondary to HIV infection, at a proportion as high as 89% of CD8+T lymphocytes expressing CD 38 in HIV/TB patients, demonstrating the high state of activation of these cells. Thus, whereas HIV/TB resulted in a decrease of CD 8 + T cell counts, the marked upregulation of CD 38 remains as high as in HIV-infected patients, as a result of both HIV infection and TB.
